You are here

  • Home
  • Archive
  • Volume 31, Issue 10
  • Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Article info

Article menu
Download PDFPDF
Clinical trial
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Authors

  • Lucia Musacchio Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Vanda Salutari Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Sandro Pignata Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy PubMed articlesGoogle scholar articles
  • Elena Braicu Department of Gynaecologic Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • David Cibula Department of Obstetrics and Gynaecology, General University Hospital, Prague, Czech Republic PubMed articlesGoogle scholar articles
  • Nicoletta Colombo Gynecologic Oncology Program; European Institute of Oncology, IRCCS, University of Milan-Bicocca, Milan, Italy PubMed articlesGoogle scholar articles
  • Jean Sebastien Frenel Department of Medical Oncology, Institut de Cancerologie de l'Oust site Renè Gauducheau, Saint Herblain, France PubMed articlesGoogle scholar articles
  • Flora Zagouri Oncology Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  • Vittoria Carbone Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Viola Ghizzoni Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Serena Giolitto Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Elena Giudice Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Maria Teresa Perri Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Caterina Ricci Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Giovanni Scambia Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy PubMed articlesGoogle scholar articles
  • Domenica Lorusso Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Domenica Lorusso, Policlinico Gemelli, Rome, Italy; domenica.lorusso{at}policlinicogemelli.it
View Full Text

Citation

Musacchio L, Salutari V, Pignata S, et al
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
International Journal of Gynecologic Cancer 2021;31:1369-1373.

Publication history

  • Accepted April 21, 2021
  • First published October 4, 2021.
Online issue publication 
October 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.